Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2026 Vol. 4 > No. 1 > 100189
Next Article Previous Article
COMMENTARY   Open Access     Cite

From aspirin to clopidogrel monotherapy: A new paradigm for secondary prevention in coronary artery disease

  • 1.

    Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

  • 2.

    National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

  • 3.

    Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

  • 4.

    Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing 100070, China

  • 5.

    These authors contributed equally

More Information
  • Corresponding authors: wanganxin@bjtth.org (A.W.);  mengxia45@163.com (X.M.)
  • Received Date:  November 10, 2025
    Accepted Date:  January 05, 2026
    Published Online:  January 06, 2026
The Innovation Medicine  4(1),  https://doi.org/10.59717/j.xinn-med.2026.100189  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Valgimigli M., Choi K.H., Giacoppo D., et al. (2025). Clopidogrel versus aspirin for secondary prevention of coronary artery disease: A systematic review and individual patient data meta-analysis. Lancet 406:1091−1102. DOI:10.1016/s0140-6736(25)01562-4

    View in Article CrossRef Google Scholar

    [2] Virani S.S., Newby L.K., Arnold S.V., et al. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American heart association/American college of cardiology joint committee on clinical practice guidelines. Circulation 148:e9−e119. DOI:10.1161/cir.0000000000001168

    View in Article CrossRef Google Scholar

    [3] Vrints C., Andreotti F., Koskinas K.C., et al. (2024). 2024 ESC guidelines for the management of chronic coronary syndromes. Eur. Heart J. 45:3415−3537. DOI:10.1093/eurheartj/ehae177

    View in Article CrossRef Google Scholar

    [4] Wang Y., Zhao X., Lin J., et al. (2016). Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 316:70−78. DOI:10.1001/jama.2016.8662

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Wang A., Tian X., Cheng S., et al. (2026). From aspirin to clopidogrel monotherapy: A new paradigm for secondary prevention in coronary artery disease. The Innovation Medicine 4:100189. https://doi.org/10.59717/j.xinn-med.2026.100189
    Wang A., Tian X., Cheng S., et al. (2026). From aspirin to clopidogrel monotherapy: A new paradigm for secondary prevention in coronary artery disease. The Innovation Medicine 4:100189. https://doi.org/10.59717/j.xinn-med.2026.100189

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(3355) PDF downloads(882)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.